Pharmacy World and Science

, Volume 26, Issue 6, pp 324–327 | Cite as

The efficacy of octreotide LAR (long acting release) treatment in patients with somatotropinoma, and mixed pituitary tumours

  • Ryszard WaśkoEmail author
  • Paweł Bolko
  • Maciej Owecki
  • Magdalena Jaskuła
  • Jerzy Sowiński


Objective: The efficacy of somatostatin analogues in the treatment of acromegaly is not always equal and therefore we wanted to evaluate the efficacy of therapy with octreotide long acting release (LAR) in patients with monohormonal tumours (somatotropinomas) in comparison to individuals with mixed pituitary tumours secreting alphasubunit.

Method: The 35 acromegalic patients (18 males and 17 females), aged 41.8 ± 8.8 years, were divided into 2 groups according to the secreted hormones: 1 with mixed pituitary tumours with elevated growth hormone and alpha-subunit concentrations, the other with isolated growth hormone hypersecretion and normal alpha-subunit levels. The groups included 19 patients (9 males and 10 females), aged 40.1 ± 7.1 years (mean ± SD), and 16 patients (9 males and 7 females) aged 43.8 ± 8.8 years (mean ± SD), respectively.

Results: The decrease of GH and IGF-I levels after octreotide LAR treatment were observed in both groups. However, the reduction of GH and IGF-I concentrations was not equal in both groups and the differences between both groups were statistically significant (P=0.01 for GH levels, and P=0.047 for IGF-I levels).

Conclusions: After octreotide LAR treatment, the decrease of GH level and of mean IGF-I values was greater in patients with mixed pituitary tumours and high alpha-subunit concentrations than in patients with isolated GH hypersecretion and normal alpha-subunit levels.

Acromegaly Alpha subunit Octreotide Pharmacotherapy Pituitary tumours Somatostatin analogues 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Harris AG. Acromegaly and its management. Philadelphia: Lippincott-Raven Publishers, 1996.Google Scholar
  2. 2.
    Freda PU. How effective are current therapies for acromegaly? Growth Horm IGF Res 2003; 13(Suppl A): S144–51.CrossRefGoogle Scholar
  3. 3.
    de Herder WW, Lamberts SW. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol 2002; 14: 53–7.CrossRefGoogle Scholar
  4. 4.
    Biermasz NR, van den Oever NC, Frolich M, Arias AM, Smit JW, Romijn JA et al. Sandostatin LAR in acromegaly: a 6 week injections interval suppresses GH secretion as effectively as 4-week interval. Clin Endocrinol 2003; 58: 288–95.CrossRefGoogle Scholar
  5. 5.
    Ballare E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 2001; 86: 3809–14.CrossRefGoogle Scholar
  6. 6.
    Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H et al. Prognostic and therapeuthic consequences of Gs? mutations in somatotroph adenomas. J Clin Endocrinol Metab 1998; 83: 1604–10.CrossRefGoogle Scholar
  7. 7.
    Lania A, Montovani G, Spada A. Genetics of pituitary tumors: focus on g-protein mutations. Exp Biol Med 2003; 228: 1004–7.Google Scholar
  8. 8.
    Pawlikowski M, Pisarek H, Kunert-Radek J, Radek A. Immunohistochemical detection of somatostatin receptor subtypes in clinically nonfunctioning pituitary ademonas. Endocr Pathol 2003; 14: 231–8.Google Scholar
  9. 9.
    Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L et al. Bim-23244. a somatostatin receptor subtype 2-and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001; 86:140–5.CrossRefGoogle Scholar
  10. 10.
    Raynor K, Murphy WA, Coly DH, Taylor JE, Moreau JP, Yasuda K. Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity of linear peptides. Mol Pharmacol 1993; 43: 838–44.PubMedGoogle Scholar
  11. 11.
    Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M et al. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone supression identify different tumoral phenotypes. J Clin Endocrinol Metab 2000; 85: 781–92.CrossRefGoogle Scholar
  12. 12.
    Reubi JC, Landolt AM. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab 1989; 68: 844–50.Google Scholar
  13. 13.
    Corbetta S, Ballare E, Mantovani G, Lania A, Losa M, Di Blasio AM et al. Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression. Eur J Clin Invest 2001; 31: 208–14.CrossRefGoogle Scholar
  14. 14.
    Saveanu A, Morange-Ramos I, Gunz G, Dufour H, Enjalbert A, Jaquet P. A luteinizing hormone-, alpha-subunit-and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies. Eur J Endocrinol 2001; 145: 35–41.CrossRefGoogle Scholar
  15. 15.
    Giusti M, Bocca L, Florio T, Foppiani L, Corsaro A, Auriati L et al. Cabergoline modulation of alpha-subunits and FSH secretion in a gonadotroph adenoma. J Endocrinol Invest 2000; 23: 463–6.Google Scholar
  16. 16.
    Katznelson L. Oppenheim DS. Coughlin JF, Kliman B, Schoenfeld DA, Klibanski A. Chronic somatostatin analog administration in patients with alpha subunit-secreting pituitary tumours. J Clin Endocrinol Metab 1992; 75: 1318–25.CrossRefGoogle Scholar
  17. 17.
    Andersen M, Bjerre P, Schroder HD, Edal A, Hoilund-Carlsen PF, Pedersen PH et al. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Clin Endocrinol 2001; 54: 23–30.CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Ryszard Waśko
    • 1
    Email author
  • Paweł Bolko
    • 1
  • Maciej Owecki
    • 1
  • Magdalena Jaskuła
    • 1
  • Jerzy Sowiński
    • 1
  1. 1.Department of Endocrinology, Metabolism and Internal MedicinePoznań University of Medical SciencesPoland

Personalised recommendations